<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2008.23.5.833</article-id><article-id pub-id-type="pmid">18955790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Low Frequency and Variability of <italic>FLT3</italic> Mutations in Korean Patients with Acute Myeloid Leukemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bang</surname><given-names>Soo-Mee</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Jeong Yeal</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jiyoon</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Se Hoon</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jinny</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Eun Kyung</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Dong Bok</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Jae Hoon</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Soo Jin</given-names></name><xref ref-type="aff" rid="A4">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Jeon</surname><given-names>In Sang</given-names></name><xref ref-type="aff" rid="A5">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yeo-Kyeoung</given-names></name><xref ref-type="aff" rid="A6">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyeoung Joon</given-names></name><xref ref-type="aff" rid="A6">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hee-Nam</given-names></name><xref ref-type="aff" rid="A7">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Il-Kwon</given-names></name><xref ref-type="aff" rid="A7">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Hyoung Jin</given-names></name><xref ref-type="aff" rid="A8">**</xref></contrib><contrib contrib-type="author"><name><surname>Shin</surname><given-names>Hee Young</given-names></name><xref ref-type="aff" rid="A8">**</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Hyo Seop</given-names></name><xref ref-type="aff" rid="A8">**</xref></contrib></contrib-group><aff id="A1">Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</aff><aff id="A2"><label>*</label>Department of Laboratory Medicine, Gachon University Gil Hospital, Incheon, Korea.</aff><aff id="A3"><label>&#x02020;</label>Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea.</aff><aff id="A4"><label>&#x02021;</label>Department of Pediatrics, Gachon University Gil Hospital, Incheon, Korea.</aff><aff id="A5"><label>&#x000a7;</label>Department of Laboratory Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.</aff><aff id="A6"><label>&#x02016;</label>Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea.</aff><aff id="A7"><label>&#x000b6;</label>Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Korea.</aff><aff id="A8"><label>**</label>Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.</aff><author-notes><corresp> Address for correspondence: Jae Hoon Lee, M.D. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Korea. Tel: +82.32-460-2186, Fax: +82.32-460-3233, <email>jhlee@gilhospital.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>30</day><month>10</month><year>2008</year></pub-date><volume>23</volume><issue>5</issue><fpage>833</fpage><lpage>837</lpage><history><date date-type="received"><day>10</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><italic>FLT3</italic> mutations are common genetic changes, and are reported to have prognostic significance in acute myeloid leukemia (AML). The <italic>FLT3</italic> internal tandem duplication (ITD) and the D835 activating mutation in the tyrosine kinase domain (TKD) were analyzed by polymerase chain reaction (PCR) in the genomic DNA of Korean patients with AML at diagnosis and during follow-up. There were 226 patients with AML enrolled between March 1996 and August 2005. The incidence of ITD and TKD at diagnosis was 13% (29/226) and 3% (6/226). When compared to Western and other Asian patients with AML, Korean patients had a lower frequency by about two-thirds of ITD and TKD. Among the non-M3 cases (N=203), the patients with an ITD had a significantly shorter event-free survival when compared with those without an ITD (<italic>p</italic>=0.0079). Among 54 relapsed patients, 9 patients had the <italic>FLT3</italic> ITD at diagnosis. Six patients demonstrated a reappearance of the ITD and 3 patients remained negative at relapse. One patient, among 45 patients who relapsed, had a negative baseline ITD but acquired a <italic>de novo</italic> ITD at relapse. There were 101 samples from 93 patients in remission; they were all negative for an ITD. Among 34 patients who failed to achieve a remission, five patients had a persistent ITD and one patient had a <italic>de novo</italic> ITD. These results support the concept of resistance of <italic>FLT3</italic> ITD leukemic clones to chemotherapy. Therefore, effective therapy with <italic>FLT3</italic> targeting agents may improve the prognosis of non-M3 AML patients with the <italic>FLT3</italic> mutation.</p></abstract><kwd-group><kwd>FLT3 Mutations</kwd><kwd>Internal Tandem Duplication</kwd><kwd>Tyrosine Kinase Domain Mutation</kwd><kwd>Leukemia, Myeloid, Acute</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p><italic>FLT3</italic> mutations are common cytogenetic changes in acute myeloid leukemia (AML). Internal tandem duplication (ITD) of exon 14 or 15 is detected in 20-30% of patients (<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>) and a mutation of D835 in exon 20 in 7% of patients (<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>). Many clinical studies have shown that patients with an ITD at diagnosis have frequent disease relapse and a short duration of survival when compared to patients without an ITD (<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B17">17</xref>). Two prior Korean trials included 165 adult (<xref ref-type="bibr" rid="B14">14</xref>) and 61 pediatric (<xref ref-type="bibr" rid="B16">16</xref>) patients with AML, and showed similar results; patients with an ITD at diagnosis had reduced event-free survival and similar overall survival when compared to patients without an ITD. The incidence of ITD in the 2 Korean studies was 35.2% and 6.6%, respectively (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>). A second mutation of <italic>FLT3</italic> involves the tyrosine kinase domain (TKD) at D835. Its incidence is relatively low and its prognostic value has not been determined (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B18">18</xref>). However, one of several studies on TKD showed that the survival of patients with TKD at diagnosis was longer than those without TKD (<xref ref-type="bibr" rid="B18">18</xref>).</p><p>Several studies have investigated the variability of the <italic>FLT3</italic> mutation in patients with AML during treatment (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>). When compared to diagnosis, leukemic relapse occurred with persistent, newly developed or disappeared ITD. Because of the small number of patients in prior studies, the understanding of the <italic>FLT3</italic> changes is incomplete. In addition, the role of the <italic>FLT3</italic> status in disease remission or persistence during therapy has not been evaluated. Therefore, we studied <italic>FLT3</italic> mutations (ITD and TKD) at diagnosis and evaluated their variability during disease remission relapse or persistence with therapy in Korean patients with AML.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Eligibility</title><p>From March 1996 to August 2005, 226 patients from three centers were diagnosed with AML and underwent induction chemotherapy according to the center's protocol usually including anthracycline and cytarabine. Among them, 33 patients did not receive chemotherapy. Twenty-four patients did not receive chemotherapy due to co-morbid conditions or advanced age, and pretreatment mortality occurred in nine patients. All patients' bone marrow (BM) samples at diagnosis were available, but samples after induction were available for 111 patients. BM samples were classified into four groups: Group A samples at diagnosis, Group B first relapse or more, Group C first remission or more, and Group D first induction failure or more. The number of patient samples available at diagnosis and relapse was 54 for A/B, 91 for A/C and 28 for A/D. All patients provided informed consent and the individual institutional review boards at each center approved the study protocol.</p></sec><sec><title>Detection of <italic>FLT3</italic> ITD and TKD</title><p>Mononuclear cells from the BM aspirate were isolated using Histopaque-1077 (Sigma, St. Louis, MO, U.S.A.) and then DNA was extracted using the QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) for the ITD was carried out as described previously (<xref ref-type="bibr" rid="B1">1</xref>). We used a 100 ng sample of each patient's DNA, which was amplified in a 36-cycle PCR reaction at an annealing temperature of 56&#x02103;. We used 10 &#x000b5;M/L of two reverse primers (11R of 5'-ACTCTA AATTTTCTCT-3', and 12R of 5'-CTTTCAGCATTTTGACGGCAACC-3') for each reaction and 10 &#x000b5;M/ L of a common forward primer (3'-GCAATTTAGGTATGAAAGCCAGC-5'). The PCR for TKD was performed as described previously (<xref ref-type="bibr" rid="B3">3</xref>). We amplified exon 17 of the <italic>FLT3</italic> gene by the genomic PCR method using the primers (17F of 5'-CCGCCAGGAACGTGCTTG-3', and 17R of 5'-GCAG-CCTCACATTGCCCC-3'). Amplified products were digested with <italic>Eco</italic> RV; then they were subjected to electrophoresis on an agarose gel.</p></sec><sec><title>Statistical analysis</title><p>The correlation of the clinical characteristics and the <italic>FLT3</italic> ITD or TKD mutations at diagnosis was analyzed in 226 patients with AML, including or excluding those with M3 disease. Differences in the median variables of age, peripheral white blood cell (WBC) counts, platelet counts and the serum lactate dehydrogenase (LDH) concentration were analyzed by the Mann-Whitney U test. The analysis of data frequencies was performed using the Fisher's exact test for 2 &#x000d7; 2 tables or the chi-square test for larger tables. Survival probabilities were estimated by the Kaplan-Meyer method, and differences in the survival distributions were evaluated by the log-rank test. These statistical analyses were performed with SPSS software, version 13.0 (Chicago, IL, U.S.A.). For all analyses, the <italic>p</italic> values were 2-tailed, and a <italic>p</italic> value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Clinical characteristics of AML patients with or without <italic>FLT3</italic> mutations</title><p>Among the 226 AML patients, 29 (12.8%) had an ITD, 6 (2.7%) had a TKD and 191 (84.5%) had neither (wild type). No patient had an ITD and TKD concomitantly. When compared to patients with the wild type, the patients with an ITD or a TKD were significantly older (<italic>p</italic>=0.020) and had higher WBC (<italic>p</italic>=0.008) counts. Their subtypes were most frequently from M0 to M5. The presence of <italic>FLT3</italic> mutations was not related to gender, previous hematological disease, cytogenetic changes, or high serum LDH (<xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec><title>The effect of <italic>FLT3</italic> mutations on remission and survival</title><p>Among the 193 patients receiving induction chemotherapy, 182 patients were available to evaluate for remission and 151 patients achieved complete remission; the remission rate (RR) was 78%. Nine patients died of therapy-related complications within 30 days. Among 22 patients with an ITD at diagnosis, 19 patients achieved remission. There was no significant difference in the RR between patients with an ITD and the wild type (<italic>p</italic>=0.651). Therefore, the presence of a <italic>FLT3</italic> mutation did not influence the RR (<italic>p</italic>=0.824).</p><p>At a median follow-up of 61 (11-123) months, 90 of the 236 patients (39.8%) were still alive. The median overall survival (OS) was 14 (95% CI, 12-17), 14 (4-23) and 14 (10-18) months in all patients, those with an ITD and those with the wild type, respectively (<italic>p</italic>=0.530). The median event-free survival (EFS) was 10 (8-12), 7 (2-11) and 11 (7-14) months for all patients, those with an ITD and those with the wild type, respectively (<italic>p</italic>=0.094). When excluding the M3 types (N=20), comparison of the OS between the ITD and wild type patients showed no difference; however, the EFS with an ITD was significantly shortened (<italic>p</italic>=0.0079, <xref ref-type="fig" rid="F1">Fig. 1</xref>). In the multivariate analysis in treated non-M3 patients (N=176), the significant factors influencing the OS and the EFS were cytogenetic risk group (<xref ref-type="bibr" rid="B23">23</xref>), the presence of a complete remission after the first induction and post-remission transplantation either autologous or allogeneic (<xref ref-type="table" rid="T2">Table 2</xref>). However, neither a <italic>FLT3</italic> mutation nor an ITD affected survival in this analysis.</p></sec><sec><title>Variability of the <italic>FLT3</italic> mutation</title><p>The changes of the <italic>FLT3</italic> ITD are summarized in <xref ref-type="fig" rid="F2">Fig. 2</xref>. At hematological remission, all samples were negative for an ITD even if there was an initially positive ITD (N=14). The ITD reappeared with relapse in 6 out of 9 patients, and was de novo in one of 45 patients. Induction failures with a persistent ITD were common. One patient had a lately occurred ITD at the second induction failure. The TKD changes were evaluated in patients from one center. Among 23 samples at relapse, two had a TKD. One patient had a TKD initially, and it reappeared on relapse. The other patient had an ITD only at diagnosis, and showed a newly appeared TKD at remission, which persisted at relapse and during the refractory period despite negative conversion of ITD.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our study showed a low frequency of <italic>FLT3</italic> ITD and TKD, 12.8% and 2.7%, respectively, in Korean AML patients. This frequency was about two-thirds lower than reports from other Asian and Western patients. (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B24">24</xref>). A recent Korean study on M3 disease showed a relatively low frequency of ITD and TKD, 12.0% and 9.3% (<xref ref-type="bibr" rid="B25">25</xref>). Another unpublished Korean report also showed a low frequency of the <italic>FLT3</italic> mutation in AML patients, the ITD was 10.4% and the TKD was 9.1% (<xref ref-type="bibr" rid="B26">26</xref>). To determine the association with age, we separated the patients into 148 adults and 72 pediatric patients. The adult group had the <italic>FLT3</italic> mutation in 16% of cases and the pediatric group in 6%. Previous reports showed the <italic>FLT3</italic> mutation in 20-30% of adults and in 9-11.5% of pediatric aged patients (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Therefore, the information to date shows that the frequency of the <italic>FLT3</italic> mutation, especially the ITD, is low in Korean AML patients in both the adult and pediatric age groups.</p><p>The prognostic value of the <italic>FLT3</italic> mutation in AML was evaluated in a group of patients with normal karyotypes excluding those with known prognostic cytogenetic changes. About half of the AML patients had a normal karyotype or an intermediate cytogenetic risk (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B29">29</xref>). The <italic>FLT3</italic> ITD at diagnosis in these patients was associated with a significantly shortened EFS and OS (<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B17">17</xref>). Therefore, intensified consolidation including transplantation or clinical trials targeting the <italic>FLT3</italic> mutation should be considered in patients with an ITD (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). The variability of the <italic>FLT3</italic> ITD, during treatment in this study, supports a pattern of reappearance of the ITD with disease relapse and persistent ITD in refractory disease, which suggests chemo-resistance of the ITD-positive leukemic clones.</p><p>Our study included only 20 patients with M3. Recently several studies reported that M3 patients with ITD had a poor survival (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B32">32</xref>). Clinical trials with <italic>FLT3</italic>-targeting agents to ATRA and anthracycline-based treatment may provide more information on the role of <italic>FLT3</italic> in M3.</p><p>Although a more sensitive method for detection of ITD, such as the genescan technique, (<xref ref-type="bibr" rid="B21">21</xref>) was not used in our trial, all samples at remission were negative for ITD. In a follow-up to our study (data not included) genescan detected ITD in three out of 101 samples at remission. Therefore, future studies should use the more sensitive methods now available instead of the PCR.</p><p>In summary, this study included the largest number of Korean patients with AML to date, and showed a relatively low frequency of <italic>FLT3</italic> ITD consistent with prior reports. ITD in Korean non-M3 AML patients was associated with poor EFS. In addition, the variability of ITD, during treatment follow-up, suggested chemo-resistance of the ITD-positive leukemic clones. Therefore, aggressive therapeutic approaches should be considered in AML patients with ITD at diagnosis.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We particularly thank Hee Geun Kang, R.N. and Jung In Jue, R.N. for assistance with the data management.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Iwai</surname><given-names>T</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Horiike</surname><given-names>S</given-names></name><name><surname>Kashima</surname><given-names>K</given-names></name><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Fujimoto</surname><given-names>T</given-names></name><name><surname>Misawa</surname><given-names>S</given-names></name></person-group><article-title>Internal tandem duplication of the flt3 gene found in acute myeloid leukemia</article-title><source>Leukemia</source><year>1996</year><volume>10</volume><fpage>1911</fpage><lpage>1918</lpage><pub-id pub-id-type="pmid">8946930</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Iwai</surname><given-names>T</given-names></name><name><surname>Misawa</surname><given-names>S</given-names></name><name><surname>Okuda</surname><given-names>T</given-names></name><name><surname>Sonoda</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Kahsima</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>Y</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><article-title>Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodyplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines</article-title><source>Leukemia</source><year>1997</year><volume>11</volume><fpage>1605</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">9324277</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><article-title>FLT3 in human hematologic malignancies</article-title><source>Leuk Lymphoma</source><year>2002</year><volume>43</volume><fpage>1541</fpage><lpage>1547</lpage><pub-id pub-id-type="pmid">12400596</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Kodera</surname><given-names>Y</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Asou</surname><given-names>N</given-names></name><name><surname>Kuriyama</surname><given-names>K</given-names></name><name><surname>Yagasaki</surname><given-names>F</given-names></name><name><surname>Shimazaki</surname><given-names>C</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Motoji</surname><given-names>T</given-names></name><name><surname>Shinagawa</surname><given-names>K</given-names></name><name><surname>Takeshita</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>R</given-names></name><name><surname>Ohno</surname><given-names>R</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><article-title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>2434</fpage><lpage>2439</lpage><pub-id pub-id-type="pmid">11290608</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Duhier</surname><given-names>FM</given-names></name><name><surname>Goodeve</surname><given-names>AC</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>Care</surname><given-names>RS</given-names></name><name><surname>Peake</surname><given-names>IR</given-names></name><name><surname>Reilly</surname><given-names>JT</given-names></name></person-group><article-title>Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia</article-title><source>Br J Haematol</source><year>2001</year><volume>113</volume><fpage>983</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">11442493</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Bagrintseva</surname><given-names>K</given-names></name><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name><name><surname>Hiddemann</surname><given-names>W</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name></person-group><article-title>A new recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>3423</fpage><lpage>3425</lpage><pub-id pub-id-type="pmid">12384447</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stirewalt</surname><given-names>DL</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name></person-group><article-title>The role of FLT3 in haematopoietic malignancies</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>650</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">12951584</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiede</surname><given-names>C</given-names></name><name><surname>Steudel</surname><given-names>C</given-names></name><name><surname>Mohr</surname><given-names>B</given-names></name><name><surname>Schaich</surname><given-names>M</given-names></name><name><surname>Schakel</surname><given-names>U</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name><name><surname>Wermke</surname><given-names>M</given-names></name><name><surname>Bornhauser</surname><given-names>M</given-names></name><name><surname>Ritter</surname><given-names>M</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Ehninger</surname><given-names>G</given-names></name><name><surname>Illmer</surname><given-names>T</given-names></name></person-group><article-title>Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>4326</fpage><lpage>4335</lpage><pub-id pub-id-type="pmid">12036858</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Minami</surname><given-names>S</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Asou</surname><given-names>N</given-names></name><name><surname>Kuriyama</surname><given-names>K</given-names></name><name><surname>Jinnai</surname><given-names>I</given-names></name><name><surname>Shimazaki</surname><given-names>C</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Oh</surname><given-names>H</given-names></name><name><surname>Motoji</surname><given-names>T</given-names></name><name><surname>Omoto</surname><given-names>E</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>R</given-names></name><name><surname>Ueda</surname><given-names>R</given-names></name></person-group><article-title>Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>3074</fpage><lpage>3080</lpage><pub-id pub-id-type="pmid">10216104</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boissel</surname><given-names>N</given-names></name><name><surname>Cayuela</surname><given-names>JM</given-names></name><name><surname>Preudhomme</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>X</given-names></name><name><surname>Grardel</surname><given-names>N</given-names></name><name><surname>Fund</surname><given-names>X</given-names></name><name><surname>Tigaud</surname><given-names>I</given-names></name><name><surname>Raffoux</surname><given-names>E</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Sigaux</surname><given-names>F</given-names></name><name><surname>Degos</surname><given-names>L</given-names></name><name><surname>Castaigne</surname><given-names>S</given-names></name><name><surname>Fenaux</surname><given-names>P</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name></person-group><article-title>Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><fpage>1699</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">12200684</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kottaridis</surname><given-names>PD</given-names></name><name><surname>Gale</surname><given-names>RE</given-names></name><name><surname>Frew</surname><given-names>ME</given-names></name><name><surname>Harrison</surname><given-names>G</given-names></name><name><surname>Langabeer</surname><given-names>SE</given-names></name><name><surname>Belton</surname><given-names>AA</given-names></name><name><surname>Walker</surname><given-names>H</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><name><surname>Bowen</surname><given-names>DT</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Goldstone</surname><given-names>AH</given-names></name><name><surname>Linch</surname><given-names>DC</given-names></name></person-group><article-title>The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>1752</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">11535508</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kainz</surname><given-names>B</given-names></name><name><surname>Heintel</surname><given-names>D</given-names></name><name><surname>Marculescu</surname><given-names>R</given-names></name><name><surname>Schwarzinger</surname><given-names>I</given-names></name><name><surname>Sperr</surname><given-names>W</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Weltermann</surname><given-names>A</given-names></name><name><surname>Fonatsch</surname><given-names>C</given-names></name><name><surname>Haas</surname><given-names>OA</given-names></name><name><surname>Mannhalter</surname><given-names>C</given-names></name><name><surname>Lechner</surname><given-names>K</given-names></name><name><surname>Jaeger</surname><given-names>U</given-names></name></person-group><article-title>Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)</article-title><source>Hematol J</source><year>2002</year><volume>3</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">12522450</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Dugas</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>W</given-names></name><name><surname>Staib</surname><given-names>P</given-names></name><name><surname>Wuchter</surname><given-names>C</given-names></name><name><surname>Loffler</surname><given-names>H</given-names></name><name><surname>Sauerland</surname><given-names>CM</given-names></name><name><surname>Serve</surname><given-names>H</given-names></name><name><surname>Buchner</surname><given-names>T</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name><name><surname>Hiddemann</surname><given-names>W</given-names></name></person-group><article-title>Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">12070009</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>YR</given-names></name><name><surname>Lee</surname><given-names>IK</given-names></name><name><surname>Lee</surname><given-names>HN</given-names></name><name><surname>Kim</surname><given-names>NY</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name></person-group><article-title>The presence of FLT3/ITD mutations is an independent prognostic factor in acute myeloid leukemia patients with normal karyotype</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>3008a</fpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>I</given-names></name><name><surname>Martin</surname><given-names>G</given-names></name><name><surname>Bolufer</surname><given-names>P</given-names></name><name><surname>Barragan</surname><given-names>E</given-names></name><name><surname>Rueda</surname><given-names>E</given-names></name><name><surname>Roman</surname><given-names>J</given-names></name><name><surname>Fernandez</surname><given-names>P</given-names></name><name><surname>Leon</surname><given-names>P</given-names></name><name><surname>Mena</surname><given-names>A</given-names></name><name><surname>Cervera</surname><given-names>J</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Sanz</surname><given-names>MA</given-names></name></person-group><article-title>Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia</article-title><source>Haematologica</source><year>2003</year><volume>88</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12551822</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Hong</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>IH</given-names></name><name><surname>Park</surname><given-names>BK</given-names></name><name><surname>Han</surname><given-names>KS</given-names></name><name><surname>Cho</surname><given-names>HI</given-names></name><name><surname>Shin</surname><given-names>HY</given-names></name><name><surname>Ahn</surname><given-names>HS</given-names></name></person-group><article-title>Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia</article-title><source>Leuk Res</source><year>2005</year><volume>29</volume><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">15863200</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>Y</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Asou</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>R</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Naoe</surname><given-names>T</given-names></name></person-group><article-title>Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene</article-title><source>Br J Haematol</source><year>1999</year><volume>104</volume><fpage>659</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">10192423</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>A</given-names></name><name><surname>Linch</surname><given-names>D</given-names></name><name><surname>Hills</surname><given-names>R</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><name><surname>Burnett</surname><given-names>A</given-names></name><name><surname>Gale</surname><given-names>R</given-names></name></person-group><article-title>Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>334a</fpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>LY</given-names></name><name><surname>Huang</surname><given-names>CF</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>TL</given-names></name><name><surname>Dunn</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>PN</given-names></name><name><surname>Kuo</surname><given-names>MC</given-names></name><name><surname>Lai</surname><given-names>CL</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name></person-group><article-title>Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse</article-title><source>Blood</source><year>2002</year><volume>100</volume><fpage>2387</fpage><lpage>2392</lpage><pub-id pub-id-type="pmid">12239146</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovland</surname><given-names>R</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Bruserud</surname><given-names>O</given-names></name></person-group><article-title>Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases</article-title><source>Leuk Lymphoma</source><year>2002</year><volume>43</volume><fpage>2027</fpage><lpage>2029</lpage><pub-id pub-id-type="pmid">12481903</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiesmeier</surname><given-names>J</given-names></name><name><surname>Muller-Tidow</surname><given-names>C</given-names></name><name><surname>Westermann</surname><given-names>A</given-names></name><name><surname>Czwalinna</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Krauter</surname><given-names>J</given-names></name><name><surname>Heil</surname><given-names>G</given-names></name><name><surname>Ganser</surname><given-names>A</given-names></name><name><surname>Serve</surname><given-names>H</given-names></name><name><surname>Verbeek</surname><given-names>W</given-names></name></person-group><article-title>Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy</article-title><source>Leuk Res</source><year>2004</year><volume>28</volume><fpage>1069</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">15289019</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloos</surname><given-names>J</given-names></name><name><surname>Zwaan</surname><given-names>CM</given-names></name><name><surname>Corthals</surname><given-names>SL</given-names></name><name><surname>Goemans</surname><given-names>BF</given-names></name><name><surname>Waisfisz</surname><given-names>Q</given-names></name><name><surname>Creutzig</surname><given-names>U</given-names></name><name><surname>Reinhardt</surname><given-names>D</given-names></name><name><surname>Hahlen</surname><given-names>K</given-names></name><name><surname>Kaspers</surname><given-names>GJL</given-names></name></person-group><article-title>FLT3/internal tandem duplication in paired presentation and relapse pediatric AML</article-title><source>Blood</source><year>2004</year><volume>102</volume><fpage>334a</fpage></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimwade</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>H</given-names></name><name><surname>Oliver</surname><given-names>F</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><name><surname>Harrison</surname><given-names>C</given-names></name><name><surname>Harrison</surname><given-names>G</given-names></name><name><surname>Rees</surname><given-names>J</given-names></name><name><surname>Hann</surname><given-names>I</given-names></name><name><surname>Stevens</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>A</given-names></name><name><surname>Goldstone</surname><given-names>A</given-names></name></person-group><article-title>The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>2322</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">9746770</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients</article-title><source>Leuk Res</source><year>2005</year><volume>29</volume><fpage>1393</fpage><lpage>1398</lpage><pub-id pub-id-type="pmid">15996732</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>CJ</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Seo</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Chi</surname><given-names>HS</given-names></name></person-group><article-title>Inferior prognostic outcome in acute promyelocytic leukemia with alteration of FLT3 gene</article-title><source>Leuk Lymphoma</source><year>2006</year><volume>47</volume><fpage>1788</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">17064989</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>SY</given-names></name><name><surname>Ki</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Hong</surname><given-names>SA</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Analysis of FLT3-activiating mutations in 77 patients with acute myelogenous leukemia; association with WHO classification</article-title><source>Korean J Hematol</source><year>2003</year><volume>38</volume><fpage>44a</fpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwaan</surname><given-names>CM</given-names></name><name><surname>Meshinchi</surname><given-names>S</given-names></name><name><surname>Radich</surname><given-names>JP</given-names></name><name><surname>Veerman</surname><given-names>AJ</given-names></name><name><surname>Huismans</surname><given-names>DR</given-names></name><name><surname>Munske</surname><given-names>L</given-names></name><name><surname>Podleschny</surname><given-names>M</given-names></name><name><surname>Hahlen</surname><given-names>K</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Reinhardt</surname><given-names>D</given-names></name><name><surname>Harbott</surname><given-names>J</given-names></name><name><surname>Creutzig</surname><given-names>U</given-names></name><name><surname>Kaspers</surname><given-names>GJ</given-names></name><name><surname>Griesinger</surname><given-names>F</given-names></name></person-group><article-title>FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>2387</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">12816873</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacayo</surname><given-names>NJ</given-names></name><name><surname>Meshinchi</surname><given-names>S</given-names></name><name><surname>Raimondi</surname><given-names>SC</given-names></name><name><surname>Kuo</surname><given-names>DJ</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>MN</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Ravindranath</surname><given-names>Y</given-names></name><name><surname>Sikic</surname><given-names>BI</given-names></name><name><surname>Weinstein</surname></name><name><surname>Dahl</surname><given-names>GV</given-names></name></person-group><article-title>FLT3 mutations determine the clinical outcome in children with de novo acute myelogenous leukemia (AML) and normal karyotype: Pediatric Oncology Group (POG) Study # 9421</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>570a</fpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slovak</surname><given-names>ML</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Cassileth</surname><given-names>PA</given-names></name><name><surname>Harrington</surname><given-names>DH</given-names></name><name><surname>Theil</surname><given-names>KS</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Head</surname><given-names>DR</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name><name><surname>Forman</surname><given-names>SJ</given-names></name><name><surname>Appelbaum</surname><given-names>FR</given-names></name></person-group><article-title>Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>4075</fpage><lpage>4083</lpage><pub-id pub-id-type="pmid">11110676</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>RE</given-names></name><name><surname>Hills</surname><given-names>R</given-names></name><name><surname>Pizzey</surname><given-names>AR</given-names></name><name><surname>Kottaridis</surname><given-names>PD</given-names></name><name><surname>Swirsky</surname><given-names>D</given-names></name><name><surname>Gilkes</surname><given-names>AF</given-names></name><name><surname>Nugent</surname><given-names>E</given-names></name><name><surname>Mills</surname><given-names>KI</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><name><surname>Solomon</surname><given-names>E</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Linch</surname><given-names>DC</given-names></name><name><surname>Grimwade</surname><given-names>D</given-names></name></person-group><article-title>NCRI Adult Leukaemia Working Party. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>3768</fpage><lpage>3776</lpage><pub-id pub-id-type="pmid">16105978</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sternberg</surname><given-names>DW</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name></person-group><article-title>Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges</article-title><source>Curr Opin Hematol</source><year>2005</year><volume>12</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15604885</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuchenbauer</surname><given-names>F</given-names></name><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Kern</surname><given-names>W</given-names></name><name><surname>Hiddemann</surname><given-names>W</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name></person-group><article-title>Impact of FLT3 mutations and promyelocytic leukaemiabreakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia</article-title><source>Br J Haematol</source><year>2005</year><volume>130</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">16029447</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Event-free survival according to <italic>FLT3</italic>-ITD in 206 patients with non-M3 AML.</p></caption><graphic xlink:href="jkms-23-833-g001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><p>Changes of <italic>FLT3</italic>-ITD during follow-up.</p><p>ITD<sup>+</sup>, <italic>FLT3</italic>-ITD positive, and ITD<sup>-</sup>, <italic>FLT3</italic> wild type. A (numeral)/B (numeral) means a number of patients with <italic>FLT3</italic>-ITD/tested patients.</p></caption><graphic xlink:href="jkms-23-833-g002"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient and disease characteristics according to <italic>FLT3</italic> mutational status</p></caption><graphic xlink:href="jkms-23-833-i001"/><table-wrap-foot><fn><p><sup>*</sup>, <italic>FLT3</italic> internal tandem duplication (ITD) or D835 point mutation of tyrosine kinase domain (TKD) was identified in this group; <sup>&#x02020;</sup>, mixed means biphenotypic or bilineage leukemia.</p><p>RAEB-t, refractory anemia with excess blast in transformation; CBC, complete blood count; LDH, latacte dehydrogenase.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Multivariate analysis of the significant factors for event-free (EFS) and overall survival (OS) in treated non-M3 patients (N=176)</p></caption><graphic xlink:href="jkms-23-833-i002"/><table-wrap-foot><fn><p>HR, hazard ratio; Cyto, cytogenetic 3 risk groups consisted of favorable, intermediate, and adverse risk groups; 1st CR, complete hematologic remission to the first induction treatment; SCT, stem cell transplantation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>